An experimental PROTAC drug designed to degrade mutant KRASG12D produced tumor responses in patients with advanced non–small cell lung cancer and pancreatic ductal adenocarcinoma in a phase I trial, with limited toxicity. Investigators are now testing the therapy in combination regimens and later-stage studies as competition intensifies among companies developing drugs against the common cancer driver.
A Sat, study studied this question.